Vaccine-derived polioviruses and the endgame strategy for global polio eradication

Annual Review of Microbiology

Volumn 59, Issue , 2005, Pages 587-635

  Kew, Olen M ^a   Sutter, Roland W ^b   De Gourville, Esther M ^b   Dowdle, Walter R ^c   Pallansch, Mark A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Task Force for Child Survival and Development   (United States)

Author keywords

Attenuation of neurovirulence; Oral poliovirus vaccine; Poliomyelitis

Indexed keywords

INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE;

DEVELOPING COUNTRY; DRUG INDUCED DISEASE; EPIDEMIC; ERADICATION THERAPY; HEALTH PROGRAM; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; NONHUMAN; PHENOTYPE; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVERTANT; REVIEW; RISK FACTOR; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS; VACCINE DERIVED POLIOVIRUS; VIRUS EXCRETION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; WORLD HEALTH ORGANIZATION;

HEALTH POLICY; HUMANS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

POLIOVIRUS;

EID: 27144546976     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.58.030603.123625     Document Type: Review

References (232)

1. Agol VI, Pilipenko EV, Slobodskaya OR. 1996. Modification of translational control elements as a new approach to design of attenuated picornavirus strains. J. Biotechnol. 44:119-28
2. Alexander JP Jr, Gary HE Jr, Pallansch MA. 1997. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175(Suppl. 1):S176-82
3. Alexander LN, Seward JF, Santibanez TA, Pallansch MA, Kew OM, et al. 2004. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292:1696-701
4. Andrus JK, de Quadros C, Olivé JM, Hull HF. 1992. Screening of cases of acute flaccid paralysis for poliomyelitis eradication: ways to improve specificity. Bull. WHO 70:591-96
5. Andrus JK, Strebel PM, de Quadros CA, Olivé JM. 1995. Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91. Bull. WHO 73:33-40
6. Anonymous. 1980. Studies on new attenuated strains of type III live poliomyelitis vaccine. I. Development of a new type III attenuated poliovirus. Chin. Med. J. 93:583-90
7. Aylward RB, Cochi SL. 2004. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bull. WHO 82:40-46
8. Aylward RB, Porta D, Fiore L, Ridolfi B, Chierchini P, Forastiere F. 1997. Unimmunized Gypsy populations and implications for the eradication of poliomyelitis in Europe. J. Infect. Dis. 175(Suppl. 1):S86-88
9. Balanant J, Guillot S, Candréa A, Delpeyroux F, Crainic R. 1991. The natural genomic variability of poliovirus analyzed by a restriction fragment polymorphism assay. Virology 184:645-54
10. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. 1999. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265:178-84
11. Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberley I, Barrera-Oro J, et al. 1967. Studies on the immunogenicity, communicability, and genetic stability of oral poliovaccine administered during the winter. Am. J. Epidemiol. 86:112-36
12. Blomqvist S, Savolainen C, Laine P, Hirttio P, Lamminsalo E, et al. 2004. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J. Virol. 78:4876-83
13. Bodian D, Morgan IM, Howe HA. 1949. Differentiation of types of poliomyelitis viruses. III. The grouping of fourteen strains into three basic immunologic types. Am. J. Hyg. 49:234-45
14. Bouchard MJ, Lam DH, Racaniello VR. 1995. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin strain. J. Virol. 69:4972-78
15. Brown BA, Oberste MS, Maher K, Pallansch M. 2003. Complete genornic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the non-capsid coding region. J. Virol. 77:8973-84
16. Brown F. 2001. Progress in polio eradication: vaccine strategies for the end game. Dev. Biol.:105
17. Cabasso VJ, Jervis GA, Moyer AW, Roca-Garcia M, Orsi EV, Cox HR. 1959. Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. In Live Poliovirus Vaccines. 1st Int. Conf. Live Poliovirus Vaccines, pp. 102-34. Washington, DC: Pan Am. Sanit. Bur.
18. Cammack N, Phillips A, Dunn G, Patel V, Minor PD. 1988. Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167:507-14
19. Cent. Dis. Control Prevent. 1994. Certification of poliomyelitis eradication-the Americas, 1994. Morbid. Mortal. Wkly. Rep. 43:720-22
20. Cent. Dis. Control Prevent. 1997. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Wkly. Rep. 46(No. RR-3):1-25
21. Cent. Dis. Control Prevent. 2000. Developing and expanding contributions of the Global Laboratory Network for Poliomyelitis Eradication, 1997-1999. Morbid. Mortal. Wkly. Rep. 49:156-60
22. Cent. Dis. Control Prevent. 2001. Certification of poliomyelitis eradication-Western Pacific Region, October 2000. Morbid. Mortal. Wkly. Rep. 50:1-3
23. Cent. Dis. Control Prevent. 2002. Certification of poliomyelitis eradication-European Region, June 2002. Morbid. Mortal. Wkly. Rep. 51:572-74
24. Cent. Dis. Control Prevent. 2004. National laboratory inventory for global poliovirus containment-United States, November 2003. Morbid. Mortal. Wkly. Rep. 53:457-59
25. Cherkasova E, Laassri M, Chizhikov V, Korotkova E, Dragunsky E, et al. 2003. Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc. Natl. Acad. Sci. USA 100:9398-403
26. Cherkasova EA, Korotkova EA, Yakovenko ML, Ivanova OE, Eremeeva TP, et al. 2002. Long-term circulation of vaccine-derived poliovirus that causes paralytic disease. J. Virol. 76:6791-99
27. Cherkasova EA, Yakovenko ML, Rezapkin GV, Korotkova EA, Ivanova OE, et al. 2005. Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine. J. Virol. 79:1062-70
28. Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran YX, Levenbook IS. 1992. RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J. Virol. 66:966-70
29. Cochi SL, Sutter RW, Kew OM, Pallansch MA, Dowdle WR. 1997. A decision tree for stopping polio immunization. Techn. Consult. Global Erad. Poliomyelitis. Rep. EPI/POLIO/TECH.97/IVP18. Geneva: WHO
30. Cooper PD. 1968. A genetic map of poliovirus temperature-sensitive mutants. Virology 35:584-96
31. Crainic R, Couillin P, Blondel B, Cabau N, Boue A, Horodniceanu F. 1983. Natural variation of poliovirus neutralization epitopes. Infect. Immun. 41:1217-25
32. Cruz RR. 1984. Cuba: mass polio vaccination program, 1962-1982. Rev. Infect. Dis. 6(Suppl. 2):S408-12
33. Cuervo NS, Guillot S, Romanenkova N, Combiescu M, Aubert-Combiescu A, et al. 2001. Genomic features of intertypic recombinant Sabin poliovirus strains excreted by primary vaccinees. J. Virol. 75:5740-51
34. da Silva EE, da Costa EV, Kew OM. 2000. OPV-derived polioviruses isolated from recent cases of acute flaccid paralysis in Brazil are closely related to the prototype Sabin strains. Presented at Progr. Polio Eradication: Vaccine Strategies End Game, Paris, 28-30 June
35. De L, Nottay BK, Yang C-F, Holloway BP, Pallansch MA, Kew O. 1995. Identification of vaccine-related polioviruses by hybridization with specific RNA probes. J. Clin. Microbiol. 33:562-71
36. De L, Yang C-F, da Silva E, Boshell J, Caceres P, et al. 1997. Genotype-specific RNA probes for the direct identification of wild polioviruses by blot hybridization. J. Clin. Microbiol. 35:2834-40
37. Delbrück M. 1958. Bacteriophage genetics. In Poliomyelitis: Papers and Discussion Presented at the Fourth International Poliomyelitis Conference, ed. IP Conference, pp. 342-53. Philadelphia: Lippincott
38. de Quadros CA, Andrus JK, Olivé JM, Guerra de Macedo C, Henderson DA. 1992. Polio eradication from the Western Hemisphere. Annu. Rev. Public Health 13:239-52
39. Deshpande JM, Shetty SJ, Siddiqui ZA. 2003. Environmental surveillance system to track wild poliovirus transmission. Appl. Environ. Microbiol. 69:2919-27
40. Doi Y, Abe S, Yamamoto H, Horie H, Ohyama H, et al. 2001. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev. Biol. 105:163-69
41. Domingo E, Holland JJ. 1997. RNA virus mutations and fitness for survival. Annu. Rev. Microbiol. 51:151-78
42. Dowdle WR, Birmingham ME. 1997. The biologic principles of poliovirus eradication. J. Infect. Dis. 175(Suppl. 1):S286-92
43. Dowdle WR, de Gourville E, Kew OM, Pallansch MA, Wood DJ. 2003. Polio eradication: the OPV paradox. Rev. Med. Virol. 13:277-91
44. Dowdle WR, Wolff C, Sanders R, Lambert S, Best M. 2004. Will containment of wild poliovirus in laboratories and inactivated poliovirus vaccine production sites be effective for global certification? Bull. WHO 82:59-62
45. Drake JW, Holland JJ. 1999. Mutation rates among RNA viruses. Proc. Natl. Acad. Sci. USA 96:13910-13
46. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Cáceres VM, Jafari H, et al. 2005. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Assess. In press
47. Ehrenfeld E, Teterina NL. 2002. Initiation of translation of picornavirus RNAs: structure and function of the internal ribosome entry site. See Ref. 175a, pp. 159-69
48. El Bassioni L, Barakat I, Nasr E, de Gourville EM, Hovi T, et al. 2003. Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am. J. Epidemiol. 158:807-15
49. Enders J, Weller T, Robbins F. 1949. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109:85-87
50. Enders JF, Weller TH, Robbins FC. 1952. Alterations in pathogenicity for monkeys of Brunhilde strain of poliomyelitis virus following cultivation in human tissues. Fed. Proc. 11:467
51. Esteves K. 1988. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull. WHO 66:739-46
52. Fenner F, Henderson DA, Arita I, Ježek Z, Ladnyi ID. 1988. Smallpox and Its Eradication. Geneva: WHO
53. Ferguson M, Wood DJ, Minor PD. 1993. Antigenic structure of poliovirus in inactivated vaccines. J. Gen. Virol. 74:685-90
54. Filman DJ, Syed R, Chow M, Macadam AJ, Minor PD, Hogle JM. 1989. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 8:1567-79
55. Fine PEM, Carneiro IAM. 1999. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am. J. Epidemiol. 150:1001-21
56. Fine PEM, Oblapenko G, Sutler RW. 2004. Polio control after certification: major issues outstanding. Bull. WHO 82:47-52
57. FDA. 1991. Additional standards for viral vaccines; poliovirus vaccine live oral; final rule (21 CFR Part 630). Fed. Regist. 56:21418-38
58. Pricks CE, Icenogle JP, Hogle JM. 1985. Trypsin sensitivity of the Sabin strain type 1 poliovirus: cleavage sites in virions and related particles. J. Virol. 54:856-59
59. Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. 1993. Polioviruses with natural recombinant genomes isolated from vaccine-associated poliomyelitis. Virology 196:199-208
60. Gavrilin GV, Cherkasova EA, Lipskaya GY, Kew OM, Agol VI. 2000. Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model. J. Virol. 74:7381-90
61. Georgescu MM, Balanant J, Macadam A, Otelea D, Combiescu M, et al. 1997. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J. Virol. 71:7758-68
62. Gromeier M, Alexander L, Wimmer E. 1996. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl. Acad. Sci. USA 93:2370-75
63. Gromeier M, Bessert B, Arita M, Nomoto A, Wimmer E. 1999. Dual stem loops within the poliovirus internal ribosome entry site controls neurovirulence. J. Virol. 73:958-64
64. Gromeier M, Nomoto A. 2002. Determinants of poliovirus pathogenesis. See Ref. 175a, pp. 367-79
65. Guest S, Pilipenko E, Sharma K, Chumakov K, Roos RP. 2004. Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J. Virol. 78:11097-107
66. Guillot S, Caro V, Cuervo N, Korotkova E, Combiescu M, et al. 2000. Natural genetic exchanges between vaccine and wild poliovirus strains in humans. J. Virol. 74:8434-43
67. Hadler SC, Cochi SL, Bilous J, Cutts FT. 2004. Vaccination programs in developing countries. See Ref. 151a, pp. 1407-41
68. Haller AA, Stewart SR, Semler BL. 1996. Attenuation stem-loop lesions in the 5′ noncoding region of poliovirus RNA: neuronal cell-specific translation defects. J. Virol. 70:1467-74
69. Halsey NA, Pinto J, Espinosa-Rosales F, Faure-Fontenia MA, da Sil E, et al. 2004. Search for poliovirus carriers in persons with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. WHO 82:3-8
70. Hammon WM, Coriell LL, Wehrle PF, Stokes J Jr. 1953. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. JAMA 151:1272-85
71. Hara M, Saito Y, Komatsu T, Kodama H, Abo W, et al. 1981. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiol. Immunol. 25:905-13
72. He Y-N, Bowman VD, Mueller S, Bator CM, Bella J, et al. 2000. Interaction of the poliovirus receptor with poliovirus. Proc. Natl. Acad. Sci. USA 97:79-84
73. Henderson DA, Borio LL, Lane JM. 2004. Smallpox and vaccinia. See Ref. 151a, pp. 123-53
74. Hennessey KA, Lago H, Diomande F, Akoua-Koffi C, Caceres VM, et al. 2005. Poliovirus vaccine shedding among persons with HIV, Côte d'Ivorie. J. Infect. Dis. In press
75. Hidalgo S, Garcia Erro M, Cisterna D, Freire MC. 2003. Paralytic poliomyelitis caused by a vaccine-derived polio virus in an antibody-deficient Argentinean child. Pediatr. Infect. Dis. J. 22:570-72
76. Hogle JM. 2002. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu. Rev. Microbiol. 56:677-702
77. Hogle JM, Chow M, Filman DJ. 1985. The three-dimensional structure of poliovirus at 2.9 Å resolution. Science 229:1358-65
78. Horstmann DM, McCollum RW, Mascola AD. 1954. Viremia in human poliomyelitis. J. Exp. Med. 99:355-69
79. Hovi T, Stenvik M. 1994. Selective isolation of poliovirus in recombinant murine cell line expressing the human poliovirus receptor gene. J. Clin. Microbiol. 32:1366-68
80. Hull HF, Ward NA, Milstien JB, de Quadros C. 1994. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 343:1331-37
81. Iizuka N, Kohara M, Hagino-Yamagishi K, Abe S, Komatsu T, et al. 1989. Construction of less neurovirulent polioviruses by introducing deletions into the 5′ noncoding region of the genome. J. Virol. 63:5354-63
82. Joce R, Wood D, Brown D, Begg N. 1992. Paralytic poliomyelitis in England and Wales, 1985-91. Br. Med. J. 305:79-82
83. Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, et al. 1989. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1302-9
84. Kew OM, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, et al. 2002. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296:356-59
85. Kew OM, Mulders MN, Lipskaya GY, da Silva EE, Pallansch MA. 1995. Molecular epidemiology of polioviruses. Semin. Virol. 6:401-14
86. Kew OM, Nottay BK. 1984. Molecular epidemiology of polioviruses. Rev. Infect. Dis. 6(Suppl. 2):S499-504
87. Kew OM, Pallansch MA. 2002. The mechanism of polio eradication. See Ref. 175a, pp. 481-91
88. Kew OM, Sutter RW, Nottay B, McDonough M, Prevots DR, et al. 1998. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36:2893-99
89. Kew OM, Wright PF, Agol VI, Delpeyroux F, Shimizu H, et al. 2004. Circulating vaccine-derived polioviruses: current state of knowledge. Bull. WHO 82:16-23
90. Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, et al. 2003. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 188:1845-52
91. Kilpatrick DR, Ching K, Iber J, Campagnoli R, Freeman CJ, et al. 2004. Multiplex PCR method for identifying recombinant vaccine-related polioviruses. J. Clin. Microbiol. 42:4313-15
92. Kilpatrick DR, Nottay B, Yang C-F, Yang S-J, da Silva E, et al. 1998. Serotype-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 36:352-57
93. Kilpatrick DR, Nottay B, Yang C-F, Yang S-J, Mulders MN, et al. 1996. Group-specific identification of polioviruses by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy. J. Clin. Microbiol. 34:2990-96
94. Kim-Farley R, Bart K, Schonberger L, Orenstein W, Hinman A, et al. 1984. The epidemiology of poliomyelitis in the United States: virtual elimination of disease caused by wild virus. Lancet 2:315-17
95. Kinnunen L, Huovilainen A, Pöyry T, Hovi T. 1990. Rapid molecular evolution of wild type 3 poliovirus during infection in individual hosts. J. Gen. Virol. 71:317-24
96. Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, et al. 1981. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291:547-53
97. 96a. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, et al, eds. 2001. Field's Virology. Philadelphia: Lippincott Williams & Wilkins
98. Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A. 1988. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain. J. Virol. 62:2828-35
99. Kohler KA, Banerjee K, Hlady GW, Andrus JK, Sutter RW. 2002. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull. WHO 80:210-16
100. Koprowski H, Jervis GA, Norton TW. 1952. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. Am. J. Hyg. 55:108-26
101. Korotkova EA, Park R, Cherkasova EA, Lipskaya GY, Chumakov KM, et al. 2003. Retrospective analysis of a local cessation of vaccination against poliomyelitis: a possible scenario for the future. J. Virol. 77:12460-65
102. Kostrewski J, Kulesza A, Abgarowicz A. 1970. The epidemic of type 3 poliomyelitis in Poland in 1968. Epidemiol. Rev. 24:89-103
103. Kuechler E, Seipelt J, Liebig H-D, Sommergruber W. 2002. Picornavirus proteinase-mediated shutoff of host cell translation: direct cleavage of a cellular initiation factor. See Ref. 175a, pp. 301-11
104. Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, et al. 1997. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes. Structure 5:961-78
105. Li CP, Schaeffer M. 1954. Isolation of a non-neurotropic variant of type 1 poliomyelitis virus. Proc. Soc. Exp. Biol. Med. 87:148-53
106. Lipskaya GY, Chervonskaya EA, Belova GI, Maslova SV, Kutateladze TN, et al. 1995. Geographic genotypes (geotypes) of poliovirus case isolates from the former Soviet Union: relatedness to other known poliovirus genotypes. J. Gen. Virol. 76:1687-99
107. Lipskaya GY, Muzychenko AR, Kutitova OK, Maslova SV, Equestre M, et al. 1991. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine-associated polio cases. J. Med. Virol. 35:290-96
108. Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Kew OM, Pallansch MA. 2003. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. J. Virol. 77:10994-1005
109. Liu H-M, Zheng D-P, Zhang L-B, Oberste MS, Pallansch MA, Kew OM. 2000. Molecular evolution of a type 1 wild-vaccine poliovirus recombinant during widespread circulation in China. J. Virol. 74:11153-61
110. Macadam AJ, Arnold C, Hewlett J, John A, Marsden S, et al. 1989. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172:408-14
111. Macadam AJ, Ferguson G, Stone DM, Meredith J, Almond JW, Minor PD. 2001. Live-attenuated strains of improved genetic stability. Dev. Biol. 105:179-87
112. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, et al. 1993. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18-26
113. MacCallum FO. 1971. Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in the protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia. Spec. Rep. Ser. Med. Res. Counc. 310:72-85
114. MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, et al. 2004. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509-13
115. Majiyagbe J. 2004. The volunteers' contribution to polio eradication. Bull. WHO 82:2
116. Manor Y, Handsher R, Halmut T, Neuman M, Abramovitz B, et al. 1999. A double-selective tissue culture system for isolation of wild-type poliovirus from sewage applied in a long-term environmental surveillance. Appl. Environ. Microbiol. 65:94-97
117. Manor Y, Handsher R, Halmut T, Neuman M, Bobrov A, et al. 1999. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian Authority. J. Clin. Microbiol. 37:1670-75
118. Martin J, Dunn G, Hull R, Patel V, Minor PD. 2000. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74:3001-10
119. Martin J, Ferguson GL, Wood DJ, Minor PD. 2000. The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. Virology 278:42-49
120. Martín J, Odoom K, Tuite G, Dunn G, Hopewell N, et al. 2004. Long-term excretion of vaccine-derived poliovirus by a healthy child. J. Virol. 78:13839-47
121. Más Lago P. 1999. Eradication of poliomyelitis in Cuba: a historical perspective. Bull. WHO 77:681-87
122. Melnick JL. 1978. Advantages and disadvantages of the killed and live poliomyelitis vaccines. Bull. WHO 56:21-38
123. Mendelsohn CL, Wimmer E, Racaniello VR. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855-65
124. Minor P. 2001. Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies. Dev. Biol. 105:75-80
125. Minor PD. 1990. Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161:121-54
126. Minor PD. 2004. Polio eradication, cessation of vaccination and re-emergence of disease. Nat. Rev. Microbiol. 2:473-82
127. Minor PD, Almond JW. 2002. Poliovirus vaccines: molecular biology and immune response. See Ref. 175a, pp. 381-90
128. Minor PD, Dunn G. 1988. The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. J. Gen. Virol. 69:1091-96
129. Minor PD, Dunn G, Evans DMA, Magrath DI, John A, et al. 1989. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J. Gen. Virol. 70:1117-23
130. Minor PD, John A, Ferguson M, Icenogle JP. 1986. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J. Gen. Virol. 67:693-706
131. Misbah SA, Lawrence PA, Kurtz JB, Chapel HM. 1991. Prolonged faecal excretion of poliovirus in a nurse with common variable hypogammaglobulinaemia. Postgrad. Med. J. 67:301-3
132. 130a. Mueller S, Wimmer E. 2003. Recruitment of nectin-3 to cell-cell junctions through trans-heterophilic interaction with CD155, a vitronectin and poliovirus receptor that localizes to alpha(v)beta3integrin-containing membrane microdomains. J. Biol. Chem. 278:31251-60
133. Mulders MN, van Loon AM, van der Avoort HGAM, Riemerink JHJ, Ras A, et al. 1995. Molecular characterization of the wild poliovirus type 3 epidemic in the Netherlands (1992-93). J. Clin. Microbiol. 33:3252-56
134. Muzychenko AR, Lipskaya GY, Maslova SV, Svitkin YV, Pilipenko EV, et al. 1991. Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strains during in vivo passage: structural and functional implications. Virus Res. 21:111-22
135. Nakano JH, Hatch MH, Thieme ML, Nottay B. 1978. Parameters for differentiating vaccine-derived and wild poliovirus strains. Prog. Med. Virol. 24:78-206
136. Nathanson N, Langmuir AD. 1963. The Cutter Incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States in the spring of 1955. I. Background. Am. J. Hyg. 78:16-28
137. Nathanson N, Martin JR. 1979. The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance. Am. J. Epidemiol. 110:672-92
138. Nomoto A, Arita I. 2002. Eradication of poliomyelitis. Nat. Immunol. 3:205-8
139. Nomoto A, Iizuka N, Kohara M, Arita M. 1988. Strategy for construction of live picornavirus vaccines. Vaccine 6:134-37
140. Nomoto A, Omata T, Toyoda H, Kuge S, Horie H, et al. 1982. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc. Natl. Acad. Sci. USA 79:5793-97
141. Oker-Blom N, Penttinen K, Weckström P. 1984. Inactivated poliovirus vaccine in Finland. Rev. Infect. Dis. 6(Suppl. 2):S461-62
142. Omata T, Kohara M, Kuge S, Komatsu T, Abe S, et al. 1986. Genetic analysis of the attenuation phenotype of poliovirus type 1. J. Virol. 58:348-58
143. Page GS, Mosser AG, Hogle JM, Filman DJ, Rueckert RR, Chow M. 1988. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J. Virol. 62:1781-94
144. Pallansch MA, Roos RP. 2001. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. See Ref. 96a, pp. 723-75
145. Pan Am. Health Organ. 1959. Proc. 1st Int. Conf. Live Poliovirus Vaccines. Washington, DC: Pan Am. Health Organ.
146. Pan Am. Health Organ. 1960. Proc. 2nd Int. Conf. Live Poliovirus Vaccines. Washington, DC: Pan Am. Health Organ.
147. Pan Am. Health Organ. 1985. Director announces'campaign to eradicate poliomyelitis from the Americas by 1990. Bull. Pan Am. Health Organ. 19:21-35
148. Park RE, Yang C-F, Yang S-J, Asghar H, Nategh R, Kew OM. 2002. Molecular characterization of divergent Sabin 2-derived isolates from patients with paralysis. Rep. P13-3, Am. Soc. Virol. 21st Annu. Meet., Lexington, Kentucky
149. Patriarca PA, Sutter RW, Oostvogel PM. 1997. Outbreaks of paralytic poliomyelitis, 1976-1995. J. Infect. Dis. 175(Suppl. 1):S165-72
150. Paul AV, Mugavero J, Yin J, Hobson S, Schultz S, et al. 2000. Studies on the attenuation phenotype of polio vaccines: poliovirus RNA polymerase derived from Sabin type 1 sequence is temperature sensitive in the uridylylation of VPg. Virology 272:72-84
151. Paul JR. 1971. A History of Poliomyelitis. New Haven, CT: Yale Univ. Press
152. Payne AMM. 1961. Field safety and efficacy of live attenuated poliovirus vaccines. In Poliomyelitis: Papers and Discussion Presented at the Fifth International Poliomyelitis Conference. Philadelphia: Lippincott
153. Pipkin PA, Wood DJ, Racaniello VR, Minor PD. 1993. Characterisation of L cells expressing the human poliovirus receptor for the specific detection of polioviruses in vitro. J. Virol. Methods 41:333-40
154. 151a. Plotkin SA, Orenstein WA, eds. 2004. Vaccines. Philadelphia: Saunders
155. Plotkin SA, Vidor E. 2004. Poliovirus vaccine: inactivated. See Ref. 151a, pp. 625-49
156. Plotkin SL, Plotkin SA. 2004. A short history of vaccination. See Ref. 151a, pp. 1-15
157. Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW. 1989. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J. Virol. 63:4949-51
158. Poyry T, Stenvik M, Hovi T. 1988. Viruses in sewage waters during and after a poliomyelitis outbreak and subsequent nationwide oral poliovirus vaccination campaign in Finland. Appl. Environ. Microbiol. 54:371-74
159. Racaniello VR. 2001. Picornaviridae: the viruses and their replication. See Ref. 96a, pp. 685-722
160. Racaniello VR, Baltimore D. 1981. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 214:916-19
161. Racaniello VR, Baltimore D. 1981. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc. Natl. Acad. Sci. USA 78:4887-91
162. Racaniello VR, Ren R. 1996. Poliovirus biology and pathogenesis. Curr. Top. Microbiol. Immunol. 206:305-25
163. Ren R, Moss EG, Racaniello VR. 1991. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J. Virol. 65:1377-82
164. Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS. 1994. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 202:370-78
165. Rezapkin GV, Douthitt M, Dragunsky E, Chumakov KM. 1999. Reevaluation of nucleotide sequences of wild-type and attenuated polioviruses of type 3. Virus Res. 65:111-19
166. Rezapkin GV, Fan L, Asher DM, Fibi MR, Dragunsky EM, Chumakov KM. 1999. Mutations in Sabin 2 strain of poliovirus and stability of attenuated phenotype. Virology 258:152-60
167. Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM. 1987. Geographic distribution of wild poliovirus type 1 genotypes. Virology 160:311-22
168. Risi JB. 1984. The control of poliomyelitis in Brazil. Rev. Infect. Dis. 6(Suppl. 2):S400-3
169. Robbins FC. 2004. The history of polio vaccine development. See Ref. 151a, pp. 17-30
170. Roberts L. 2005. Infectious disease. Polio eradication effort adds new weapon to its armory. Science 307:190
171. Rosen FS, Cooper MD, Wedgwood RJP. 1995. The primary immunodeficiencies. N. Engl. J. Med. 333:431-40
172. Rousset D, Rakoto-Andrianarivelo M, Razafindratsimandresy R, Randriamanalina B, Guillot S, et al. 2003. Recombinant vaccine-derived poliovirus in Madagascar. Emerg. Infect. Dis. 9:885-87
173. Sabin AB. 1985. Oral poliovirus vaccine: history of its development and use, and current strategies to eliminate poliomyelitis from the world. J. Infect. Dis. 151:420-36
174. Sabin AB, Boulger LR. 1973. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1:115-18
175. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, et al. 1960. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 173:1521-26
176. Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL. 1954. Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am. J. Public Health 44:563-70
177. Savilahti E, Klemola T, Carlsson B, Mellander L, Stenvik M, Hovi T. 1988. Inadequacy of mucosal IgM antibodies in selective IgA deficiency: excretion of attenuated polio viruses is prolonged. J. Clin. Immunol. 8:89-94
178. Schonberger LB, Sullivan-Bolyai JZ, Bryan JA. 1978. Poliomyelitis in the United States. Adv. Neurol. 19:217-27
179. 175a. Semler BL, Wimmer E, eds. 2002. Molecular Biology of Picornaviruses. Washington, DC: ASM Press
180. Sever J. 2001. Rotary International: a partner in polio eradication. Dev. Biol. 105:105-8
181. Shimizu H, Thorley B, Paladin FJ, Brussen KA, Stambos V, et al. 2004. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 78:13512-21
182. Shimojo H. 1984. Poliomyelitis control in Japan. Rev. Infect. Dis. 6(Suppl. 2):S427-S30
183. Shulman LM, Handsher R, Yang S-J, Yang C-F, Manor J, et al. 2000. Resolution of the pathways of poliovirus type 1 transmission during an outbreak. J. Clin. Microbiol. 38:945-52
184. Shulman LM, Manor J, Handsher R, Delpeyroux F, McDonough MJ, et al. 2000. Molecular and antigenic characterization of a highly evolved derivative of the type 2 oral poliovaccine strain isolated from sewage in Israel. J. Clin. Microbiol. 38:3729-34
185. Smith J, Leke R, Adams A, Tangermann RH. 2004. Certification of polio eradication: process and lessons learned. Bull. WHO 82:24-30
186. Stanway G, Hughes PJ, Mountford RC, Reeve P, Minor PD, et al. 1984. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc. Natl. Acad. Sci. USA 81:1539-43
187. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, et al. 1992. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin. Infect. Dis. 14:568-79
188. Sutter RW, Cáceres VM, Más Lago P. 2004. The role of routine polio immunization in the post-certification era. Bull. WHO 82:31-39
189. Sutter RW, Kew OM, Cochi SL. 2004. Poliovirus vaccine: live. See Ref. 151a, pp. 651-705
190. Sutter RW, Prevots R. 1994. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect. Med. 11:426-38
191. Sutter RW, Suleiman AJM, Malankar P, Al-Khusaiby S, Mehta F, et al. 2000. Trial of a supplemental dose of four poliovirus vaccines. N. Engl. J. Med. 343:767-73
192. Svitkin Y, Cammack N, Minor PD, Almond JW. 1990. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472-U. Virology 175:103-9
193. Taffs RE, Chumakov KM, Rezapkin GV, Lu Z, Douthitt M, et al. 1995. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology 209:366-73
194. Tambini G, Andrus JK, Marques E, Boshell J, Pallansch M, et al. 1993. Direct detection of wild poliovirus transmission by stool surveys of healthy children and analysis of community wastewater. J. Infect. Dis. 168:1510-14
195. Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F. 1993. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J. Virol. 67:4630-38
196. Tech. Consult. Group WHO Glob. Erad. Poliomyelitis. 2002. "Endgame" issues for the Global Polio Eradication Initiative. Clin. Infect. Dis. 34:72-77
197. Terry L. 1962. The association of cases of poliomyelitis with the use of type 3 oral poliomyelitis vaccines. U.S. Dep. Health, Educ. Welf., Washington, DC
198. Theiler M. 1946. A mutant strain of the Lansing virus. Presented at Mech. Immun. Poliomyelitis, Baltimore, MD
199. Theiler M, Smith HH. 1937. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J. Exp. Med. 65:767-86
200. Toyoda H, Kohara M, Kataoka Y, Suganuma T, Omata T, et al. 1984. Complete nucleotide sequences of all three poliovirus serotype genomes: implication for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174:561-85
201. van der Avoort HG, Reimerink JH, Ras A, Mulders MN, van Loon AM. 1995. Isolation of epidemic poliovirus from sewage during the 1992-3 type 3 outbreak in The Netherlands. Epidemiol. Infect. 114:481-91
202. van der Avoort HGAM, Hull BP, Hovi T, Pallansch MA, Kew OM, et al. 1995. A comparative study of five methods of intratypic differentiation of polioviruses. J. Clin. Microbiol. 33:2562-66
203. van Wezel AL, Hazendonk AG. 1979. Intratypic Serodifferentiation of poliomyelitis virus by strain-specific antisera. Intervirology 11:2-8
204. van Wezel AL, van Steenis G, van der Marel P, Osterhaus AD. 1984. Inactivated poliovirus vaccine: current production methods and new developments. Rev. Infect. Dis. 6(Suppl. 2):S335-W
205. Varughese PV, Carter AO, Acres SE, Furesz J. 1989. Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Can. J. Public Health 80:363-68
206. Vonka V, Janda Z, Simon J, Adam E, Starek M. 1967. Anew type 3 attenuated poliovirus for possible use in oral poliovirus vaccine. Prog. Med. Virol. 9:204-55
207. Westrop GD, Wareham KA, Evans DM, Dunn G, Minor PD, et al. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63:1338-44
208. WHO Consult. Group. 1982. The relation between acute persisting spinal paralysis and poliomyelitis vaccine: results of a ten-year enquiry. Bull. WHO 60:231-42
209. Wimmer E, Hellen CU, Cao X. 1993. Genetics of poliovirus. Annu. Rev. Genet. 27:353-436
210. Wood DJ, Sutter RW, Dowdle WR. 2000. Stopping poliovirus vaccination after eradication: issues and challenges. Bull. WHO 78:347-57
211. World Health Assembly. 1988. Polio eradication by the year 2000. Rep. Resolution 41.28. Geneva: WHO
212. WHO. 2001. Transmission of wild poliovirus type 2: apparent global interruption. Wkly. Epidemiol. Rec. 76:95-97
213. WHO. 2002. Expanding contributions of the Global Laboratory Network for Poliomyelitis Eradication. Wkly. Epidemiol. Rec. 77:133-37
214. WHO. 2002. Progress towards the global eradication of poliomyelitis, 2001. Wkly. Epidemiol. Rec. 77:98-107
215. WHO. 2003. Conclusions and recommendations: WHO informal consultation on identification and management of vaccine-derived polioviruses. Geneva: WHO
216. WHO. 2003. Global action plan for laboratory containment of wild polioviruses. Rep. WHO/V&B/03.11. Geneva: WHO 2nd ed.
217. WHO. 2003. Global Polio Eradication Initiative, Strategic Plan 2004-2008. Geneva: WHO
218. WHO. 2003. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2002-June 2003. Wkly. Epidemiol. Rec. 78:341-48
219. WHO. 2004. Global Polio Eradication Initiative, Strategic Plan 2004-2008. Wkly. Epidemiol. Rec. 79:55-57
220. WHO. 2004. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. Wkly. Epidemiol. Rec. 79:393-98
221. WHO. 2004. Polio laboratory manual, 4th edition. Geneva: WHO
222. WHO. 2004. Poliomyelitis: imported case in Sudan, situation in northern Nigeria. Wkly. Epidemiol. Rec. 79:245-46
223. WHO. 2004. Progress towards global eradication of poliomyelitis, 2003 and January-April 2004. Wkly. Epidemiol. Rec. 79:225-34
224. WHO. 2004. Progress towards global poliomyelitis eradication: preparation for the oral poliovirus vaccine cessation era. Wkly. Epidemiol. Rec. 79:349-56
225. WHO. 2004. Special theme-polio eradication: end-stage challenges. Bull. WHO 82:1-70
226. WHO. 2005. Poliomyelitis outbreak escalates in the Sudan. Wkly. Epidemiol. Rec. 80:2-3
227. Yang C-F, Chen H-Y, Jorba J, Sun H-C, Yang S-J, et al. 2005. Recombination across multiple lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. In press
228. Yang C-F, De L, Holloway BP, Pallansch MA, Kew OM. 1991. Detection and identification of vaccine-related polioviruses by the polymerase chain reaction. Virus Res. 20:159-79
229. Yang C-F, De L, Yang S-J, Gómez JR, Cruz JR, et al. 1992. Genotype-specific in vitro amplification of sequences of the wild type 3 polioviruses from Mexico and Guatemala. Virus Res. 24:277-96
230. Yang C-F, Naguib T, Yang S-J, Nasr E, Jorba J, et al. 2003. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt, 1983 to 1993. J. Virol. 77:8366-77
231. Yoneyama T, Hagiwara A, Hara M, Shimojo H. 1982. Alteration in oligonucleotide fingerprint patterns of the viral genome in poliovirus type 2 isolated from paralytic patients. Infect. Immun. 37:46-53
232. Yoshida H, Horie H, Matsuura K, Kitamura T, Hashizume S, Miyamura T. 2002. Prevalence of vaccine-derived polioviruses in the environment. J. Gen. Virol. 83:1107-11